Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Diabetes Metab J > Volume 37(6); 2013 > Article
Obesity and Metabolic Syndrome Resistin in Rodents and Humans
Hyeong Kyu Park1, Rexford S. Ahima2
Diabetes & Metabolism Journal 2013;37(6):404-414.
Published online: December 12, 2013
  • 55 Download
  • 122 Crossref
  • 147 Scopus

1Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

2Division of Endocrinology, Diabetes and Metabolism, and the Institute for Diabetes, Obesity and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Corresponding author: Rexford S. Ahima. Division of Endocrinology, Diabetes and Metabolism, and the Institute for Diabetes, Obesity and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, 12-104 Translational Research Center, 3400 Civic Center Blvd, Bldg 421, Philadelphia, PA 19104, USA.

Copyright © 2013 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Obesity is characterized by excess accumulation of lipids in adipose tissue and other organs, and chronic inflammation associated with insulin resistance and an increased risk of type 2 diabetes. Obesity, type 2 diabetes, and cardiovascular diseases are major health concerns. Resistin was first discovered as an adipose-secreted hormone (adipokine) linked to obesity and insulin resistance in rodents. Adipocyte-derived resistin is increased in obese rodents and strongly related to insulin resistance. However, in contrast to rodents, resistin is expressed and secreted from macrophages in humans and is increased in inflammatory conditions. Some studies have also suggested an association between increased resistin levels and insulin resistance, diabetes and cardiovascular disease. Genetic studies have provided additional evidence for a role of resistin in insulin resistance and inflammation. Resistin appears to mediate the pathogenesis of atherosclerosis by promoting endothelial dysfunction, vascular smooth muscle cell proliferation, arterial inflammation, and formation of foam cells. Indeed, resistin is predictive of atherosclerosis and poor clinical outcomes in patients with coronary artery disease and ischemic stroke. There is also growing evidence that elevated resistin is associated with the development of heart failure. This review will focus on the biology of resistin in rodents and humans, and evidence linking resistin with type 2 diabetes, atherosclerosis, and cardiovascular disease.
The prevalence of obesity has increased worldwide and is associated with increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), sleep apnea, cancer, fatty liver, and other diseases. It has become clear that obesity promotes a state of chronic inflammation in white adipose tissue (WAT), which leads to insulin resistance. Obesity results in excessive lipid accumulation in adipocytes and macrophages in WAT, which plays an active role in the development of insulin resistance through the release of free fatty acids, proinflammatory cytokines, and adipokines [1]. Adipose tissue secretes adipokines that play major roles in metabolism, immunity, and inflammation. Resistin is secreted primarily by adipocytes in rodents and was initially proposed as a link between obesity and insulin resistance [2]. In humans, resistin is mainly secreted by macrophages [3], suggesting that resistin is linked to inflammation. Obesity, T2DM, and CVD have been recently recognized as chronic inflammatory disorders which may be connected to proinflammatory cytokines as well as adipokines such as resistin [4]. In this review, we will discuss the biology of resistin in rodents and humans, and focus on the evolving roles of resistin in atherosclerosis and CVD in humans.
Resistin is a cysteine-rich protein which was discovered using a screening strategy for genes down-regulated in mouse adipocytes by thiazolidinedione (TZD) drugs [2]. In rodents, resistin is primarily expressed in mature white adipocytes. Mouse resistin expression is reduced in 3T3-L1 adipocytes by TZD drugs [5,6] and insulin [5,7]. In contrast, high glucose up-regulates resistin expression in adipocytes [5,8]. There were also conflicting results showing insulin can stimulate resistin secretion in mouse adipocytes [9-11]. Resistin expression in mouse adipocytes is suppressed by inflammatory cytokines, e.g., tumor necrosis factor α (TNF-α), [5,12]. Unlike rodents, human resistin is expressed in macrophages and is induced by TNF-α [13,14]. The lack of human resistin expression in adipocytes may be due to loss of a genomic binding site for the nuclear receptor peroxisome proliferator-activated receptor γ that normally controls resistin gene (retn) expression in mouse adipocytes [15]. Dietary intake has a significant effect on the regulation of resistin in rodents. The expression of resistin is decreased in the adipose tissue during fasting, and tends to increase upon refeeding in mice [2,8,16]. Serum resistin is also reduced in fasted mice. Diet-induced obese mice have elevated circulating resistin levels, however, resistin mRNA expression is suppressed in adipose tissue in these mice. Similarly, serum resistin is increased in ob/ob mice while resistin mRNA expression is reduced [16,17].
Resistin circulates in two distinct forms in mice. A disulfide-linked hexamer of resistin is the major form, but a smaller trimeric protein is also detected. The low molecular weight form of trimer is shown to be more bioactive, significantly decreasing hepatic insulin sensitivity during pancreatic clamp study [18]. However, oligomerization is required for the inhibitory action of resistin on glucose uptake in mouse cardiomyocytes [19]. In humans, there are also different molecular isoforms of circulating resistin such as trimeric and oligomeric forms, and the oligomeric form of human resistin is considered to have a more potent effect on the stimulation of proinflammatory cytokines [20-22].
Several lines of evidence support a role of resistin in glucose metabolism in rodents. Circulating levels of resistin were higher in obese mice, and the administration of recombinant resistin in normal mice impaired glucose tolerance and insulin action. Furthermore, neutralization of resistin with antiresistin antibody improved insulin sensitivity in diet-induced obese mice [2]. Both central and peripheral administration of recombinant resistin, or transgenic overexpression of resistin induced hepatic insulin resistance in mice [2,23-25]. Conversely, knockdown or deletion of resistin increased hepatic insulin sensitivity in mice on high-fat diet, and in muscle and WAT in ob/ob mice, leading to a decrease in glucose production and an increase in glucose uptake from peripheral tissue [26,27]. Resistin knockout mice showed low glucose levels after fasting, associated with a decrease in expression of gluconeogenic enzymes in liver [26]. Treatment of 3T3-L1 adipocytes, murine cardiomyocytes, and cultured skeletal muscle cells with murine resistin decreased insulin-stimulated glucose uptake into the cells [2,19,28,29]. All of these findings suggest resistin plays an important role in insulin sensitivity in rodents.
Nevertheless, the resistin receptor or the intracellular signaling pathways of resistin have not yet been clearly identified. Recent studies proposed an isoform of decorin or tyrosine kinase-like orphan receptor 1 as functional resistin receptors which may regulate WAT expansion or modulate glucose homeostasis in rodents [30,31]. Murine resistin has been demonstrated to decrease the phosphorylation of AMP-activated kinase (AMPK) in liver, skeletal muscle, and WAT [24,26,32]. Inhibition of resistin, conversely, led to an increase in the phosphorylation of AMPK which is involved in glucose homeostasis. Resistin interferes with multiple steps involved in the insulin signaling cascade, including phosphorylation of insulin receptor substrates, activation of phosphatidylinositol-3-kinase (PI3K) and protein kinase B/Akt in liver, muscle, and WAT [24,32,33]. Resistin treatment in rodents induces the expression of suppressor of cytokine signaling-3, a known inhibitor of insulin signaling, in liver, muscle, and WAT [17,27,33-35]. Considering adipocyte-derived resistin is linked to insulin resistance in rodents, the potential that rodent data may be applicable to human biology has led to much scientific research.
Resistin is predominantly expressed in peripheral blood mononuclear cells (PBMCs), and its expression increases as the cells differentiate into macrophages in humans [3,14,36]. As in murine resistin, TZD drugs down-regulated the expression of human resistin in macrophages or reduced serum resistin levels [3,14,37]. Resistin expression is also found in the nonadipocyte stromal vascular fraction in WAT, fibrotic liver, and atherosclerotic lesions, indicating that macrophages are the main source of resistin in humans [38-41]. Indeed, obese individuals who are likely to have greater infiltration of macrophages in adipose tissue showed increased expression of resistin in adipose tissue samples or had higher circulating levels of resistin than in lean individuals [36,42]. Studies of obese subjects undergoing weight reduction through diet or bariatric surgery have shown inconsistent results. Serum resistin levels were reduced, or not changed, despite weight loss in obese subjects [43-45]. There were also several reports that serum resistin levels are not associated with the parameters of obesity or insulin resistance [46-48]. However, resistin levels have been associated with visceral, intrathoracic, and pericardial fat in a cross-sectional study [49].
Given the close relationship of murine resistin and insulin resistance, numerous clinical studies have examined a possible relationship of resistin and insulin resistance in obese people with or without diabetes. Since obesity and T2DM are both associated with chronic inflammation in WAT, and resistin is mainly produced by macrophages in humans, it is possible that hyperresistinemia is a contributing factor to these pathophysiological states. However, studies relating human resistin to insulin resistance, or T2DM have shown conflicting results [35,46,47,50-52]. Qatanani et al. [53] generated transgenic mice expressing human resistin via a macrophage promoter and bred them with resistin knockout mice. The humanized resistin mice developed WAT inflammation and insulin resistance, demonstrating that human resistin may link inflammatory responses and glucose homeostasis. This is consistent with prospective case-control studies showing that people with elevated baseline levels of resistin have significantly increased risk of developing T2DM even after adjusting for other risk factors [54,55].
Epidemiological studies also suggest that resistin plays a role in insulin resistance and T2DM in humans. Several single-nucleotide polymorphisms (SNPs) have been demonstrated to be associated with elevated resistin levels, and up to two-thirds of the variation of serum resistin levels may be attributable to genetic factors [56]. The -638 G>A, -420 C>G, and -358 G>A polymorphisms in the promoter region of human resistin gene (RETN) were associated with resistin levels in Japanese obese individuals [57]. In a Japanese population, the G/G genotype at SNP -420 in RETN was associated with susceptibility to T2DM and also was correlated with monocyte resistin expression and with increased serum resistin levels [58,59]. Moreover, a cross-sectional analysis of 2,078 Japanese subjects showed that plasma resistin was associated with SNP -420 and also correlated with insulin resistance [60]. The -420G and -537A alleles were associated with increased resistin levels but not with T2DM in a Korean population [61]. In the 5-year prospective study from a Chinese subjects, both -420G and +62A alleles were significant predictors of glycemic progression [62]. Although -420 C>G SNP associated with high resistin levels appears to be related to T2DM in many studies of Asian populations, the data in Caucasian populations have been conflicting [55]. An Italian study showed that the presence of -420 C/G SNP in RETN is associated with increased obesity and metabolic syndrome but not with resistin levels [63]. An American cohort of Caucasian nondiabetic subjects has shown an association of -420G allele with resistin level, but no association with insulin resistance [64]. In the Framingham Offspring Study cohort of 2,531 participants, it has been shown that not -420 C>G SNP but SNPs in the 3' region of RETN are associated with resistin levels [65]. However, El-Shal et al. [66] have recently demonstrated that both -420 C>G and +299 G>A SNP were significantly associated with resistin level, obesity, and insulin resistance in Egyptian obese subjects.
The role of human resistin in the pathogenesis of atherosclerosis is also gaining research attention. Tang et al. [67] have shown that -420 C/G SNP in RETN is associated with an increased risk of coronary artery disease (CAD) in a Chinese population. In contrast, a couple of studies of the -420 variant in Europeans and Caucasians found no correlation with carotid and coronary atherosclerosis, respectively [63,64]. The discrepancy in the results among populations might be attributable to ethnic differences.
Murine and human resistin share about 60% sequence homology. As noted before, resistin levels decrease with TZD treatment in both humans and rodents. Unlike murine resistin, human resistin is highly expressed in macrophages, and robustly induced in response to various proinflammatory stimuli such as lipopolysaccharide (LPS), TNF-α, interleukin (IL)-6, IL-1β, and resistin itself, suggesting a role for resistin in inflammation in humans [13,14,68]. Furthermore, resistin has been shown to up-regulate the expression of proinflammatory cytokines such as TNF-α, IL-6, IL-12, or monocyte chemoattractant protein (MCP)-1 in PBMC, macrophages, and hepatic stellate cells, mediated through the nuclear factor-κB signaling pathway [39,68,69]. In line with these findings, circulating resistin levels correlate with inflammatory and fibrinolytic markers such as C-reactive protein (CRP), TNF-α, IL-6, or plasminogen activator inhibitor (PAI)-1 in subjects with T2DM, coronary atherosclerosis, chronic kidney disease, rheumatoid arthritis (RA), and sepsis [14,46,48,70-73] as well as in general population [48,60,74-78]. Increased resistin levels have been observed in patients with RA and inflammatory bowel disease and shown to be associated with disease activity [22,72,78]. In addition, circulating resistin levels were elevated in patients with severe sepsis and acute pancreatitis. Interestingly, resistin was related with disease severity in patients with severe sepsis as well as acute pancreatitis, and also predicted an unfavorable outcome in nonseptic critically ill patients [73,79,80].
It is noteworthy that numerous inflammatory factors up-regulated by human resistin are known to be involved in the development of insulin resistance. Therefore, it is possible that resistin induced by inflammation may play a role in the development of insulin resistance in humans. To address this issue, Park et al. [81] generated mice lacking murine resistin but transgenic for a bacterial artificial chromosome containing human resistin (BAC-Retn), whose expression was similar to levels in humans. LPS increased serum resistin levels in this model, and resulted in mild hypoglycemia compared with mice lacking murine and human resistin. In addition, the BAC-Retn mice developed hepatic insulin resistance under chronic endotoxemia, accompanied by inflammation in liver and skeletal muscle, supporting the role of resistin in the pathophysiology of inflammation-induced insulin resistance in humans [81]. A recent study suggested that human resistin competes with LPS for binding to Toll-like receptor 4 (TLR4) which could mediate some of the proinflammatory effects of resistin [82], however, it is unknown whether TLR4 is the predominant resistin receptor in humans.
Given the evidence that resistin is found in human atherosclerotic lesions and affects vascular endothelial function [40,41,83], it is possible resistin is involved in the development of atherosclerosis and CVD. Treatment of human resistin increased proliferation and migration of human endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). Cell proliferation and migration induced by resistin in both EC and VSMC appears to be mediated through the extracellular signal-regulated kinase, PI3K, or p38 mitogen-activated protein kinase signaling pathways [84-86]. Resistin was also shown to attenuate the ability of insulin signaling, inhibit endothelial nitric-oxide synthase, and increase oxidative stress in human aortic and coronary artery EC [86,87]. In addition, resistin up-regulated the expression of adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, P-selectin, and fractalkine, and also increased proinflammatory factors such as MCP-1, PAI-1, endothelin-1, matrix metalloproteinases, and vascular endothelial growth factor receptors, and, thereby, promoted monocyte adhesion in vascular EC [17,41,83,84,88,89]. Furthermore, resistin was expressed in human atheroma samples, and increased lipid accumulation through the up-regulation of CD36 expression and an increase in cholesteryl ester deposition in human macrophages, suggesting a role of resistin as a modulator for macrophage to foam cell transformation [40,41,90,91]. In addition, resistin has been shown to induce a prothrombotic phenotype by up-regulating tissue factor expression in human coronary artery EC [92,93]. Taken together, these findings indicate that resistin may contribute to EC dysfunction, VSMC proliferation, arterial inflammation, and accumulation of cholesterol in macrophages, suggesting that resistin plays an important role in the pathogenesis and progression of atherosclerosis in humans.
There is the growing evidence that resistin is involved in the pathogenesis of CVD. Reilly et al. [48] showed that elevated resistin levels were predictive of coronary atherosclerosis, independent of CRP, in asymptomatic individuals. Resistin was associated with the presence and severity of CAD in patients undergoing coronary angiography and those with stable CAD [94,95]. Moreover, resistin predicted restenosis after coronary artery stenting and was an independent predictor of major adverse cardiovascular events in patients with CAD [96-99]. In Korean patients with acute myocardial infarction (MI), resistin was an independent predictor of all cause mortality during the mean follow-up period of 12 months [100]. A European study found that high plasma resistin levels were associated with an increased risk of MI but not with risk of ischemic stroke in healthy subjects, even after adjustment for established cardiovascular risk factors including CRP [101]. In regard to the risk of ischemic stroke, a cross-sectional study from Japan and two nested case-control studies from Europe and United States showed that resistin was significantly associated with ischemic stroke among healthy individuals [102-104]. Higher resistin levels were also associated with poorer prognosis in patients with CAD or atherothrombotic stroke [99,105-107]. More recently, an analysis of 2,313 diabetic patients of European ancestry from two cross-sectional and two prospective studies showed that high serum resistin was a risk factor for CVD and all cause mortality in patients with T2DM [108]. Interestingly, resistin was also shown to be associated with vascular inflammation measured using 18F-fluorodeoxyglucose-positron emission tomography among healthy individuals [109]. Despite some studies showing no association between resistin and CVD [110-112], a number of animal and clinical studies are strongly supporting the idea that resistin is a potential mediator of atherosclerosis and CAD in humans.
Several animal studies have investigated the effects of resistin on cardiomyocytes. Murine resistin directly reduced both basal and insulin-stimulated glucose uptake in mouse cardiomyocytes [19]. Murine resistin was shown to be up-regulated by mechanical stretch and the overexpression of resistin depressed cardiac contractility, promoting cardiac hypertrophy in rat cardiomyocytes [113,114], suggesting resistin may affect cardiac function in animal models. Regarding the effects of human resistin on cardiomyocytes, however, very few studies have been reported. Human resistin inhibited insulin-stimulated glucose uptake in isolated mouse cardiomyocytes [19]. Preconditioning with recombinant human resistin prior to ischemia significantly impaired contractile recovery during reperfusion and stimulated cardiac TNF-α secretion in isolated rat hearts, suggesting human resistin has direct cardiac actions [115]. Emerging evidence suggests that elevated resistin is associated with the development of heart failure (HF). Takeishi et al. [116] have found that resistin is correlated with the severity of HF and predicts adverse cardiac events in patients with established HF. In addition, two large cohort studies have shown that high resistin is independently associated with new-onset HF, even after adjusting for known risk factors [117-119]. However, the causal role of resistin in HF is unclear and needs further investigation.
Resistin was initially described as a link between obesity and insulin resistance in rodents. In rodents, resistin is almost exclusively expressed in white adipocytes, whereas human resistin is predominantly expressed in macrophages. The phenotypes of humanized resistin transgenic mice suggest similar roles of murine and human resistin in insulin resistance. Studies in humanized resistin transgenic mice and epidemiological data also suggest that human resistin is a potential mediator between inflammation, and insulin resistance and atherosclerosis (Fig. 1). The identification of the resistin receptor and specific signaling mechanisms will help address crucial questions concerning the biology of resistin in health and disease. Insights into the pathophysiological role of resistin will facilitate the development of novel diagnostic and treatment tools for diabetes, and inflammatory and CVDs.
This work was supported by grants P01-DK-049210 and P30-DK-19525 from the National Institutes of Health, USA.

No potential conflict of interest relevant to this article was reported.

  • 1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846. ArticlePubMedPDF
  • 2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312. ArticlePubMedPDF
  • 3. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-476. PubMed
  • 4. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867. ArticlePubMedPDF
  • 5. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51:1737-1744. ArticlePubMedPDF
  • 6. Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002;277:19754-19761. ArticlePubMed
  • 7. Haugen F, Jorgensen A, Drevon CA, Trayhurn P. Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 2001;507:105-108. ArticlePubMedPDF
  • 8. Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002;16:1920-1930. PubMed
  • 9. Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL. Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;296:383-387. ArticlePubMed
  • 10. Wolfing B, Neumeier M, Buechler C, Aslanidis C, Scholmerich J, Schaffler A. Interfering effects of insulin, growth hormone and glucose on adipokine secretion. Exp Clin Endocrinol Diabetes 2008;116:47-52. ArticlePubMed
  • 11. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 2006;3:29-34. PubMed
  • 12. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001;288:1027-1031. PubMed
  • 13. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003;309:286-290. ArticlePubMed
  • 14. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45ArticlePubMedPMC
  • 15. Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. J Biol Chem 2009;284:6116-6125. PubMedPMC
  • 16. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004;53:1671-1679. ArticlePubMedPDF
  • 17. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009;10:96-107. ArticlePubMed
  • 18. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304:1154-1158. ArticlePubMed
  • 19. Graveleau C, Zaha VG, Mohajer A, Banerjee RR, Dudley-Rucker N, Steppan CM, Rajala MW, Scherer PE, Ahima RS, Lazar MA, Abel ED. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005;280:31679-31685. ArticlePubMed
  • 20. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E, Thiery J, Kiess W, Kratzsch J. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab 2005;90:4503-4509. ArticlePubMed
  • 21. Aruna B, Islam A, Ghosh S, Singh AK, Vijayalakshmi M, Ahmad F, Ehtesham NZ. Biophysical analyses of human resistin: oligomer formation suggests novel biological function. Biochemistry 2008;47:12457-12466. ArticlePubMed
  • 22. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009;133:157-170. ArticlePubMed
  • 23. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225-230. ArticlePubMedPMC
  • 24. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232-239. ArticlePubMedPMC
  • 25. Li FP, He J, Li ZZ, Luo ZF, Yan L, Li Y. Effects of resistin expression on glucose metabolism and hepatic insulin resistance. Endocrine 2009;35:243-251. ArticlePubMedPDF
  • 26. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin. Science 2004;303:1195-1198. ArticlePubMed
  • 27. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, Ahima RS. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006;55:3083-3090. ArticlePubMedPDF
  • 28. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006;49:183-190. ArticlePubMedPDF
  • 29. Fan HQ, Gu N, Liu F, Fei L, Pan XQ, Guo M, Chen RH, Guo XR. Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles. Acta Pharmacol Sin 2007;28:410-416. ArticlePubMed
  • 30. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011;9:74-86. ArticlePubMed
  • 31. Sanchez-Solana B, Laborda J, Baladron V. Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 2012;26:110-127. ArticlePubMed
  • 32. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004;114:224-231. ArticlePubMedPMC
  • 33. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin. Mol Cell Biol 2005;25:1569-1575. ArticlePubMedPMCPDF
  • 34. Muse ED, Lam TK, Scherer PE, Rossetti L. Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest 2007;117:1670-1678. ArticlePubMedPMC
  • 35. Lazar MA. Resistin- and Obesity-associated metabolic diseases. Horm Metab Res 2007;39:710-716. ArticlePubMed
  • 36. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-2202. PubMed
  • 37. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:624-630. ArticlePubMed
  • 38. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003;300:674-678. ArticlePubMed
  • 39. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Gines P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G, Pinzani M, Marra F. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006;169:2042-2053. PubMedPMC
  • 40. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney JM, Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews JA, Zhu J, Epstein SE. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-248. ArticlePubMed
  • 41. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, Kim SJ, Kim SY, Lee HK, Park KS. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006;69:76-85. ArticlePubMed
  • 42. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, Bertelli M, Fanin E, Andrighetto G, Federspil G, Vettor R. Increased serum resistin in adults with prader-willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab 2005;90:4335-4340. ArticlePubMed
  • 43. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, Saruta T. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003;11:997-1001. ArticlePubMed
  • 44. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S, Ebenbichler CF, Stadlmann S, Moser PL, Tilg H. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009;51:765-777. ArticlePubMed
  • 45. de Luis DA, Terroba MC, Cuellar L, Conde R, Primo D, Aller R, Sagrado MG, Izaola O. Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res 2011;43:205-208. ArticlePubMed
  • 46. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88:6098-6106. ArticlePubMedPDF
  • 47. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-4856. ArticlePubMed
  • 48. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-939. ArticlePubMed
  • 49. Jain SH, Massaro JM, Hoffmann U, Rosito GA, Vasan RS, Raji A, O'Donnell CJ, Meigs JB, Fox CS. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study. Diabetes Care 2009;32:903-908. ArticlePubMedPMCPDF
  • 50. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:150-156. ArticlePubMed
  • 51. Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008;93:3165-3172. PubMedPMC
  • 52. Tsiotra PC, Tsigos C, Anastasiou E, Yfanti E, Boutati E, Souvatzoglou E, Kyrou I, Raptis SA. Peripheral mononuclear cell resistin mRNA expression is increased in type 2 diabetic women. Mediators Inflamm 2008;2008:892864ArticlePubMedPMCPDF
  • 53. Qatanani M, Szwergold NR, Greaves DR, Ahima RS, Lazar MA. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009.Article
  • 54. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, Buring JE, Gaziano JM, Liu S. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009;32:329-334. ArticlePubMedPMCPDF
  • 55. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22:259-265. ArticlePubMedPMC
  • 56. Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, Trischitta V. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. J Clin Endocrinol Metab 2006;91:2792-2795. ArticlePubMedPDF
  • 57. Azuma K, Oguchi S, Matsubara Y, Mamizuka T, Murata M, Kikuchi H, Watanabe K, Katsukawa F, Yamazaki H, Shimada A, Saruta T. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 2004;36:564-570. ArticlePubMed
  • 58. Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, Tanabe F, Shimizu I, Kato K, Nishida W, Yamada K, Tabara Y, Yasukawa M, Fujii Y, Ohashi J, Miki T, Makino H. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 2005;335:596-602. ArticlePubMed
  • 59. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W, Hashiramoto M, Kanatsuka A, Fujii Y, Ohashi J, Makino H. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 2004;75:678-686. ArticlePubMedPMC
  • 60. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K, Miki T, Makino H. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 2007;30:1501-1506. ArticlePubMedPDF
  • 61. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY, Park HJ, Shin HD, Park KS. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004;47:559-565. ArticlePubMedPDF
  • 62. Xu JY, Sham PC, Xu A, Tso AW, Wat NM, Cheng KY, Fong CH, Janus ED, Lam KS. Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin Endocrinol (Oxf) 2007;66:211-217. ArticlePubMed
  • 63. Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S, Vettoretti S, Baragetti I, Noto D, Cefalu AB, Buccianti G, Averna M, Catapano AL. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med 2007;262:104-112. ArticlePubMed
  • 64. Qasim AN, Metkus TS, Tadesse M, Lehrke M, Restine S, Wolfe ML, Hannenhalli S, Cappola T, Rader DJ, Reilly MP. Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol (Oxf) 2009;70:698-705. ArticlePubMed
  • 65. Hivert MF, Manning AK, McAteer JB, Dupuis J, Fox CS, Cupples LA, Meigs JB, Florez JC. Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes 2009;58:750-756. ArticlePubMedPMCPDF
  • 66. El-Shal AS, Pasha HF, Rashad NM. Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients. Gene 2013;515:233-238. ArticlePubMed
  • 67. Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, Cong RH, Zhu HJ, Wang B. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol (Oxf) 2008;68:82-87. ArticlePubMed
  • 68. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-5795. ArticlePubMedPDF
  • 69. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092-1101. PubMed
  • 70. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-2457. ArticlePubMedPDF
  • 71. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006;69:596-604. ArticlePubMed
  • 72. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D, Anderlova K, Muller-Ladner U, Pavelka K, Haluzik M. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458-463. ArticlePubMed
  • 73. Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 2007;35:1536-1542. ArticlePubMed
  • 74. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005;29:1315-1320. ArticlePubMedPDF
  • 75. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006;91:2755-2760. ArticlePubMed
  • 76. Qi Q, Wang J, Li H, Yu Z, Ye X, Hu FB, Franco OH, Pan A, Liu Y, Lin X. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008;159:585-593. ArticlePubMed
  • 77. Fargnoli JL, Sun Q, Olenczuk D, Qi L, Zhu Y, Hu FB, Mantzoros CS. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010;162:281-288. ArticlePubMed
  • 78. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007;19:1070-1074. ArticlePubMed
  • 79. Schaffler A, Hamer O, Dickopf J, Goetz A, Landfried K, Voelk M, Herfarth H, Kopp A, Buchler C, Scholmerich J, Brunnler T. Admission resistin levels predict peripancreatic necrosis and clinical severity in acute pancreatitis. Am J Gastroenterol 2010;105:2474-2484. ArticlePubMedPDF
  • 80. Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009;13:R95ArticlePubMedPMC
  • 81. Park HK, Qatanani M, Briggs ER, Ahima RS, Lazar MA. Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice. Diabetes 2011;60:775-783. ArticlePubMedPMCPDF
  • 82. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010;14:1419-1431. ArticlePubMed
  • 83. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-740. ArticlePubMed
  • 84. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006;70:146-157. ArticlePubMed
  • 85. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004;110:3335-3340. ArticlePubMed
  • 86. Shen YH, Zhang L, Gan Y, Wang X, Wang J, LeMaire SA, Coselli JS, Wang XL. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 2006;281:7727-7736. PubMed
  • 87. Chen C, Jiang J, Lu JM, Chai H, Wang X, Lin PH, Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010;299:H193-H201. ArticlePubMedPMC
  • 88. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, Ho LT, Kwok CF, Juan CC. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol 2011;226:2181-2188. ArticlePubMed
  • 89. Manduteanu I, Pirvulescu M, Gan AM, Stan D, Simion V, Dragomir E, Calin M, Manea A, Simionescu M. Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells. Biochem Biophys Res Commun 2010;391:1443-1448. ArticlePubMed
  • 90. Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun 2006;351:376-382. ArticlePubMed
  • 91. Rae C, Robertson SA, Taylor JM, Graham A. Resistin induces lipolysis and re-esterification of triacylglycerol stores, and increases cholesteryl ester deposition, in human macrophages. FEBS Lett 2007;581:4877-4883. ArticlePubMed
  • 92. Calabro P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R, Pacileo G, De Rosa S, Pacileo M, De Palma R, Golino P, Calabro R. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res 2011;48:59-66. ArticlePubMedPDF
  • 93. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2012;165:622-632. ArticlePubMedPMC
  • 94. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005;46:379-380. ArticlePubMed
  • 95. Wang H, Chen DY, Cao J, He ZY, Zhu BP, Long M. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J 2009;24:161-166. ArticlePubMed
  • 96. On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007;71:868-873. ArticlePubMed
  • 97. Krecki R, Krzeminska-Pakula M, Peruga JZ, Szczesniak P, Lipiec P, Wierzbowska-Drabik K, Orszulak-Michalak D, Kasprzak JD. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011;17:CR26-CR32. ArticlePubMedPMC
  • 98. Momiyama Y, Ohmori R, Uto-Kondo H, Tanaka N, Kato R, Taniguchi H, Arakawa K, Nakamura H, Ohsuzu F. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb 2011;18:108-114. ArticlePubMed
  • 99. Li L, Han JL, Mao JM, Guo LJ, Gao W. Association between serum resistin level and cardiovascular events in postmenopausal women with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl) 2013;126:1058-1062. ArticlePubMed
  • 100. Lee SH, Ha JW, Kim JS, Choi EY, Park S, Kang SM, Choi D, Jang Y, Chung N. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis 2009;20:33-39. ArticlePubMed
  • 101. Weikert C, Westphal S, Berger K, Dierkes J, Mohlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008;93:2647-2653. ArticlePubMedPDF
  • 102. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, Hata J, Tanizaki Y, Iida M, Kiyohara Y. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol 2009;8:60ArticlePubMedPMCPDF
  • 103. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, Cushman M, Rohan TE, McGinn AP, Wang T, Strickler HD, Scherer PE, Mackey R, Curb D, Ho GY. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke 2011;42:1813-1820. ArticlePubMedPMC
  • 104. Prugger C, Luc G, Haas B, Morange PE, Ferrieres J, Amouyel P, Kee F, Ducimetiere P, Empana JP. PRIME Study Group. Multiple biomarkers for the prediction of ischemic stroke: the PRIME study. Arterioscler Thromb Vasc Biol 2013;33:659-666. PubMed
  • 105. Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, Peetz D, Post F, Lackner KJ, Tiret L, Munzel T, Blankenberg S. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007;193:121-128. ArticlePubMed
  • 106. Efstathiou SP, Tsiakou AG, Tsioulos DI, Panagiotou TN, Pefanis AV, Achimastos AD, Mountokalakis TD. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007;378:78-85. ArticlePubMed
  • 107. Lee SE, Kim HS. Human resistin in cardiovascular disease. J Smooth Muscle Res 2012;48:27-35. ArticlePubMed
  • 108. Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, De Bonis C, Marucci A, Goheen E, Prudente S, Morini E, Rizza S, Kanagaki A, Fini G, Mangiacotti D, Federici M, De Cosmo S, Pellegrini F, Doria A, Trischitta V. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 2013;8:e64729ArticlePubMedPMC
  • 109. Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011;31:944-949. PubMed
  • 110. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczel S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta 2007;386:1-6. ArticlePubMed
  • 111. Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, Marz W. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 2007;66:380-386. ArticlePubMed
  • 112. Ding Q, White SP, Ling C, Zhou W. Resistin and cardiovascular disease. Trends Cardiovasc Med 2011;21:20-27. ArticlePubMed
  • 113. Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ, Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008;45:270-280. ArticlePubMedPMC
  • 114. Wang BW, Hung HF, Chang H, Kuan P, Shyu KG. Mechanical stretch enhances the expression of resistin gene in cultured cardiomyocytes via tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 2007;293:H2305-H2312. PubMed
  • 115. Rothwell SE, Richards AM, Pemberton CJ. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006;349:400-407. ArticlePubMed
  • 116. Takeishi Y, Niizeki T, Arimoto T, Nozaki N, Hirono O, Nitobe J, Watanabe T, Takabatake N, Kubota I. Serum resistin is associated with high risk in patients with congestive heart failure: a novel link between metabolic signals and heart failure. Circ J 2007;71:460-464. ArticlePubMed
  • 117. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, Meigs JB. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009;53:754-762. PubMed
  • 118. Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasan RS, Wilson PW, Harris TB. Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009;29:1144-1149. PubMedPMC
  • 119. Bhalla V, Kalogeropoulos A, Georgiopoulou V, Butler J. Serum resistin: physiology, pathophysiology and implications for heart failure. Biomark Med 2010;4:445-452. ArticlePubMed
Fig. 1
Roles of resistin in inflammation, glucose homeostasis, and cardiovascular diseases. Resistin is induced in response to various stimuli, including proinflammatory cytokines, lipopolysaccharide (LPS), and genetically determined factors. Resistin targets several types of cells, promoting inflammation, insulin resistance, and atherosclerosis. Resistin is up-regulated and secreted from PBMC and macrophages, and in turn, acts on these cells, leading to the development of insulin resistance and enhancing inflammatory processes through activation of nuclear factor (NF)-κB. Resistin contributes to the pathogenesis of atherosclerosis by disrupting vascular endothelial cellular function, and increasing proliferation of smooth muscle cells, and foam cell transformation. Resistin directly affects the function of cardiomyocytes predisposing to myocardial injury. Adapted from Schwartz et al. Trends Endocrinol Metab 2011;22:259-65, with permission from Elsevier [55]. HSC, hepatic stellate cell; MCP, monocyte chemoattractant protein; IL, interleukin; TNF, tumor necrosis factor; PBMC, peripheral blood mononuclear cell; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; ET, endothelin; VSMC, vascular smooth muscle cell; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol-3-kinase; MAPK, mitogen-activated protein kinase; TZD, thiazolidinedione.

Figure & Data



    Citations to this article as recorded by  
    • Resistin – A Plausible Therapeutic Target in the Pathogenesis of Psoriasis
      Manupati Srikanth, Mahaboobkhan Rasool
      Immunological Investigations.2024; 53(2): 115.     CrossRef
    • MHO or MUO? White adipose tissue remodeling
      Jing Yi Zhao, Li Juan Zhou, Kai Le Ma, Rui Hao, Min Li
      Obesity Reviews.2024;[Epub]     CrossRef
    • Resistin in endocrine pancreas of sheep: Presence and expression related to different diets
      Margherita Maranesi, Elisa Palmioli, Cecilia Dall'Aglio, Daniele Marini, Polina Anipchenko, Elena De Felice, Paola Scocco, Francesca Mercati
      General and Comparative Endocrinology.2024; 348: 114452.     CrossRef
    • Adipocytokines levels as potential biomarkers for discriminating patients with a diagnosis of depressive disorder from healthy controls
      Elżbieta Małujło-Balcerska, Tadeusz Pietras
      Journal of Psychiatric Research.2024; 171: 163.     CrossRef
    • Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
      Shiyun Zhang, Bingjie Zhang, Yuehua Liu, Li Li
      Lipids in Health and Disease.2024;[Epub]     CrossRef
    • The Role of Adipokines in the Control of Pituitary Functions
      Barbara Kaminska, Beata Kurowicka, Marta Kiezun, Kamil Dobrzyn, Katarzyna Kisielewska, Marlena Gudelska, Grzegorz Kopij, Karolina Szymanska, Barbara Zarzecka, Oguzhan Koker, Ewa Zaobidna, Nina Smolinska, Tadeusz Kaminski
      Animals.2024; 14(2): 353.     CrossRef
    • Adipokine imbalance and its role in the pathogenesis of novel coronavirus infection
      I. D. Bespalova, U. M. Mitrichenko, V. V. Kalyuzhin, E. S. Koroleva, Yu. I. Koshchavtseva, D. S. Romanov, D. E. Pershina
      Bulletin of Siberian Medicine.2024; 22(4): 164.     CrossRef
    • Association of adipokine levels with obesity in periodontal health and disease: A systematic review with meta‐analysis and meta‐regression
      Eswar Kandaswamy, Chun‐Teh Lee, Soumya Bardvalli Gururaj, Sachin Shivanaikar, Vinayak M. Joshi
      Journal of Periodontal Research.2024;[Epub]     CrossRef
    • Role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction
      O. N. Dzhioeva, Yu. S. Timofeev, V. A. Metelskaya, A. A. Bogdanova, T. Yu. Vedenikin, O. M. Drapkina
      Cardiovascular Therapy and Prevention.2024; 23(3): 3928.     CrossRef
    • Association of maternal body composition and diet on breast milk hormones and neonatal growth during the first month of lactation
      David Ramiro-Cortijo, Pratibha Singh, Gloria Herranz Carrillo, Andrea Gila-Díaz, María A. Martín-Cabrejas, Camilia R. Martin, Silvia M. Arribas
      Frontiers in Endocrinology.2023;[Epub]     CrossRef
    • Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus
      Branislava Rajkov, Marija Zdravković, Ana Ninić, Milica Brajković, Slobodan Klašnja, Vera Gardijan, Lidija Memon, Jelena Munjas, Marija Mihajlović, Vesna Spasojević- Kalimanovska, Vojislav Radosavljević, Miron Sopić
      Sleep and Breathing.2023; 27(5): 2031.     CrossRef
    • Fat-to-heart crosstalk in health and disease
      Fleur Lodewijks, Timothy A. McKinsey, Emma L. Robinson
      Frontiers in Genetics.2023;[Epub]     CrossRef
    • Adipokines as Diagnostic and Prognostic Markers for the Severity of COVID-19
      Thomas Grewal, Christa Buechler
      Biomedicines.2023; 11(5): 1302.     CrossRef
    • Role of adipokines in sarcopenia
      Wenhao Lu, Wenjie Feng, Jieyu Lai, Dongliang Yuan, Wenfeng Xiao, Yusheng Li
      Chinese Medical Journal.2023; 136(15): 1794.     CrossRef
    • Resistin, TNF-α, and microRNA 124-3p expressions in peripheral blood mononuclear cells are associated with diabetic nephropathy
      Amin Monjezi, Azam Khedri, Mehrnoosh Zakerkish, Ghorban Mohammadzadeh
      International Journal of Diabetes in Developing Countries.2022; 42(1): 62.     CrossRef
    • Resistin in Urine and Breast Milk: Relation to Type of Feeding and Anthropometry at 1-Month
      Irena Santosa, Hiromichi Shoji, Kentaro Awata, Yoshiteru Arai, Hiroki Suganuma, Toshiaki Shimizu
      Pediatric Reports.2022; 14(1): 86.     CrossRef
    • High Serum Levels of Resistin is Associated With Acute Cerebral Infarction
      Kee Ook Lee, Kyung-Yul Lee, Cheol-Young Lee, Ji Hoon Kim, Jaeku Kang, Hoi Young Lee, Sang-Jun Na, Seung-Hun Oh, Ji Hoe Heo
      The Neurologist.2022; 27(2): 41.     CrossRef
    • Resistin production does not affect outcomes in a mouse model of acute surgical sepsis
      Anthony S. Bonavia, Zissis C. Chroneos, Victor Ruiz-Velasco, Charles H. Lang, Partha Mukhopadhyay
      PLOS ONE.2022; 17(3): e0265241.     CrossRef
    • Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population
      Iman Akhlaghipour, Amir Reza Bina, Mohammad Reza Mogharrabi, Ali Fanoodi, Amir Reza Ebrahimian, Soroush Khojasteh Kaffash, Atefeh Babazadeh Baghan, Mohammad Erfan Khorashadizadeh, Negin Taghehchian, Meysam Moghbeli
      Human Genomics.2022;[Epub]     CrossRef
    • Synergistic Effects of Weighted Genetic Risk Scores and Resistin and sST2 Levels on the Prognostication of Long-Term Outcomes in Patients with Coronary Artery Disease
      Hsin-Hua Chou, Lung-An Hsu, Jyh-Ming Jimmy Juang, Fu-Tien Chiang, Ming-Sheng Teng, Semon Wu, Yu-Lin Ko
      International Journal of Molecular Sciences.2022; 23(8): 4292.     CrossRef
    • Hypoxia Increases the Potential for Neutrophil-mediated Endothelial Damage in Chronic Obstructive Pulmonary Disease
      Katharine M. Lodge, Arlette Vassallo, Bin Liu, Merete Long, Zhen Tong, Paul R. Newby, Danya Agha-Jaffar, Koralia Paschalaki, Clara E. Green, Kylie B. R. Belchamber, Victoria C. Ridger, Robert A. Stockley, Elizabeth Sapey, Charlotte Summers, Andrew S. Cowb
      American Journal of Respiratory and Critical Care Medicine.2022; 205(8): 903.     CrossRef
    • The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer
      Klaudia Parafiniuk, Wiktoria Skiba, Anna Pawłowska, Dorota Suszczyk, Aleksandra Maciejczyk, Iwona Wertel
      Biomedicines.2022; 10(4): 920.     CrossRef
    • Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
      Sonia Nava-Salazar, Arturo Flores-Pliego, Giovanni Pérez-Martínez, Sandra Parra-Hernández, America Vanoye-Carlo, Francisco Ibarguengoitia-Ochoa, Otilia Perichart-Perera, Enrique Reyes-Muñoz, Juan Mario Solis-Paredes, Salvador Espino y Sosa, Guadalupe Estr
      Reproductive Sciences.2022; 29(11): 3242.     CrossRef
    • Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study
      Mohammad Muzaffar Mir, Rashid Mir, Mushabab Ayed Abdullah Alghamdi, Javed Iqbal Wani, Zia Ul Sabah, Mohammed Jeelani, Vijaya Marakala, Shahzada Khalid Sohail, Mohamed O’haj, Muffarah Hamid Alharthi, Mohannad Mohammad S. Alamri
      Journal of Personalized Medicine.2022; 12(5): 735.     CrossRef
    • Immune system and sarcopenia: Presented relationship and future perspective
      Xuzhi Zhang, Hengzhen Li, Miao He, Jingyu Wang, Yuxiang Wu, Yusheng Li
      Experimental Gerontology.2022; 164: 111823.     CrossRef
    • Adipose Tissue Secretion Pattern Influences β-Cell Wellness in the Transition from Obesity to Type 2 Diabetes
      Giuseppina Biondi, Nicola Marrano, Anna Borrelli, Martina Rella, Giuseppe Palma, Isabella Calderoni, Edoardo Siciliano, Pasquale Lops, Francesco Giorgino, Annalisa Natalicchio
      International Journal of Molecular Sciences.2022; 23(10): 5522.     CrossRef
    • Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease
      Risa Wakiya, Kiyo Ueeda, Hiromi Shimada, Shusaku Nakashima, Tomohiro Kameda, Nobuyuki Miyatake, Mikiya Kato, Taichi Miyagi, Koichi Sugihara, Mao Mizusaki, Rina Mino, Norimitsu Kadowaki, Hiroaki Dobashi
      Clinical Rheumatology.2022; 41(11): 3345.     CrossRef
    • Can soy isoflavones in combination with soy protein change serum concentration of adiponectin and resistin? A systematic review and meta‐analysis on randomized clinical trials
      Mitra Hariri, Bahareh Amirkalali, Ensiyeh Mollanoroozy, Ali Gholami
      Food Science & Nutrition.2022; 10(12): 4126.     CrossRef
    • Adipokines: Deciphering the cardiovascular signature of adipose tissue
      Joseph C. Galley, Shubhnita Singh, Wanessa M.C. Awata, Juliano V. Alves, Thiago Bruder-Nascimento
      Biochemical Pharmacology.2022; 206: 115324.     CrossRef
    • Evaluation of the Anti-Obesity Effect of Zeaxanthin and Exercise in HFD-Induced Obese Rats
      Mona Al-thepyani, Salha Algarni, Hana Gashlan, Mohamed Elzubier, Lina Baz
      Nutrients.2022; 14(23): 4944.     CrossRef
    • Single High-Dose Vitamin D Supplementation as an Approach for Reducing Ultramarathon-Induced Inflammation: A Double-Blind Randomized Controlled Trial
      Jan Mieszkowski, Andżelika Borkowska, Błażej Stankiewicz, Andrzej Kochanowicz, Bartłomiej Niespodziński, Marcin Surmiak, Tomasz Waldziński, Rafał Rola, Miroslav Petr, Jędrzej Antosiewicz
      Nutrients.2021; 13(4): 1280.     CrossRef
    • Resistin mitigates stemness and metabolic profile of human adipose-derived mesenchymal stem cells via insulin resistance
      Komal Rawal, Kishan M. Purohit, Tushar P. Patel, Neeta Karont, Sarita Gupta
      Cytokine.2021; 138: 155374.     CrossRef
    • Resistin is co-secreted with adiponectin in white mouse adipocytes
      Saliha Musovic, Man Mohan Shrestha, Ali M. Komai, Charlotta S. Olofsson
      Biochemical and Biophysical Research Communications.2021; 534: 707.     CrossRef
    • Resistin: Potential biomarker and therapeutic target in atherosclerosis
      Li Zhou, Jun-Yi Li, Ping-Ping He, Xiao-Hua Yu, Chao-Ke Tang
      Clinica Chimica Acta.2021; 512: 84.     CrossRef
    • The circulating levels of CTRP1 and CTRP5 are associated with obesity indices and carotid intima-media thickness (cIMT) value in patients with type 2 diabetes: a preliminary study
      Ziba Majidi, Solaleh Emamgholipour, Abolfazl Omidifar, Soheil Rahmani Fard, Hossein Poustchi, Mehrnoosh Shanaki
      Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
    • Corylin reduces obesity and insulin resistance and promotes adipose tissue browning through SIRT-1 and β3-AR activation
      Chin-Chuan Chen, Chen-Hsin Kuo, Yann-Lii Leu, Shu-Huei Wang
      Pharmacological Research.2021; 164: 105291.     CrossRef
    • A Focused Review of the Metabolic Side-Effects of Clozapine
      Jessica W. Y. Yuen, David D. Kim, Ric M. Procyshyn, William J. Panenka, William G. Honer, Alasdair M. Barr
      Frontiers in Endocrinology.2021;[Epub]     CrossRef
    • A Negative Energy Balance Is Associated with Metabolic Dysfunctions in the Hypothalamus of a Humanized Preclinical Model of Alzheimer’s Disease, the 5XFAD Mouse
      Antonio J. López-Gambero, Cristina Rosell-Valle, Dina Medina-Vera, Juan Antonio Navarro, Antonio Vargas, Patricia Rivera, Carlos Sanjuan, Fernando Rodríguez de Fonseca, Juan Suárez
      International Journal of Molecular Sciences.2021; 22(10): 5365.     CrossRef
    • Resistin in pregnancy: Analysis of determinants in pairs of umbilical cord blood and maternal serum
      Anne Floeck, Nina Ferrari, Christine Joisten, Maria T. Puth, Brigitte Strizek, Ramona Dolscheid-Pommerich, Ulrich Gembruch, Waltraut M. Merz
      Cytokine: X.2021; 3(2): 100052.     CrossRef
    • Is resistin the master link between inflammation and inflammation-related chronic diseases?
      Mohammed Taouis, Yacir Benomar
      Molecular and Cellular Endocrinology.2021; 533: 111341.     CrossRef
    • The dynamics of human bone marrow adipose tissue in response to feeding and fasting
      Pouneh K. Fazeli, Miriam A. Bredella, Gisela Pachon-Peña, Wenxiu Zhao, Xun Zhang, Alexander T. Faje, Megi Resulaj, Sai P. Polineni, Tara M. Holmes, Hang Lee, Elizabeth K. O’Donnell, Ormond A. MacDougald, Mark C. Horowitz, Clifford J. Rosen, Anne Klibanski
      JCI Insight.2021;[Epub]     CrossRef
    • Resistin: A journey from metabolism to cancer
      Ankita Deb, Bhavana Deshmukh, Pranay Ramteke, Firoz Khan Bhati, Manoj Kumar Bhat
      Translational Oncology.2021; 14(10): 101178.     CrossRef
    • Obesity is the basis of metabolic syndrome
      A. F. Verbovoy, N. I. Verbovaya, Yu. A. Dolgikh
      Obesity and metabolism.2021; 18(2): 142.     CrossRef
    • Human Milk Metabolic Hormones: Analytical Methods and Current Understanding
      Majed A. Suwaydi, Zoya Gridneva, Sharon L. Perrella, Mary E. Wlodek, Ching Tat Lai, Donna T. Geddes
      International Journal of Molecular Sciences.2021; 22(16): 8708.     CrossRef
    • Adipokines as Immune Cell Modulators in Multiple Sclerosis
      Merel Rijnsburger, Niek Djuric, Inge A. Mulder, Helga E. de Vries
      International Journal of Molecular Sciences.2021; 22(19): 10845.     CrossRef
    • The Role of Adipokines in Cardiovascular Pathology
      Valery Podzolkov , Anna Pokrovskaya, Ulyana Bazhanova , Tatyana Vargina , Svetlana Anatolievna Knyazeva , Daria Vanina
      Open Access Macedonian Journal of Medical Sciences.2021; 9(F): 794.     CrossRef
    • Measurement of Plasma Resistin Concentrations in Horses with Metabolic and Inflammatory Disorders
      Beatriz Fuentes-Romero, Alberto Muñoz-Prieto, José J. Cerón, María Martín-Cuervo, Manuel Iglesias-García, Escolástico Aguilera-Tejero, Elisa Díez-Castro
      Animals.2021; 12(1): 77.     CrossRef
      О. I. Tokarenko, I. O. Andreieva, O. O. Tokarenko, M. M. Surmilo
      Modern medical technology.2021; (4): 11.     CrossRef
    • Alteration of gut microbiota affects expression of adiponectin and resistin through modifying DNA methylation in high-fat diet-induced obese mice
      Hongyang Yao, Chaonan Fan, Yuanyuan Lu, Xiuqin Fan, Lulu Xia, Ping Li, Rui Wang, Tiantian Tang, Yuanyuan Wang, Kemin Qi
      Genes & Nutrition.2020;[Epub]     CrossRef
    • Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin
      Zhian Sherzad Hayder, Zrar Saleem Kareem
      International Urology and Nephrology.2020; 52(4): 749.     CrossRef
    • Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation
      Ariane R. Pessentheiner, G. Michelle Ducasa, Philip L. S. M. Gordts
      Frontiers in Immunology.2020;[Epub]     CrossRef
    • Resistin Is Increased in Periodontal Cells and Tissues: In Vitro and In Vivo Studies
      Andressa V. B. Nogueira, Marjan Nokhbehsaim, Sema Tekin, Rafael S. de Molon, Luis C. Spolidorio, Svenja Memmert, Anna Damanaki, Andreas Jäger, Sigrun Eick, James Deschner, Joni A. Cirelli
      Mediators of Inflammation.2020; 2020: 1.     CrossRef
    • Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease
      Alan Chait, Laura J. den Hartigh
      Frontiers in Cardiovascular Medicine.2020;[Epub]     CrossRef
    • The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus
      Patrik Šimják, Kateřina Anderlová, Anna Cinkajzlová, Antonín Pařízek, Michal Kršek, Martin Haluzík
      Minerva Endocrinologica.2020;[Epub]     CrossRef
    • High Plasma Resistin Levels Portend the Insulin Resistance-Associated Susceptibility to Early Cognitive Decline in Patients with Type 2 Diabetes Mellitus
      Chenchen Wang, Xi Huang, Sai Tian, Rong Huang, Dan Guo, Hongyan Lin, Jiaqi Wang, Shaohua Wang
      Journal of Alzheimer's Disease.2020; 75(3): 807.     CrossRef
    • Resistin in metabolism, inflammation, and disease
      Deeksha Tripathi, Sashi Kant, Saurabh Pandey, Nasreen Z. Ehtesham
      The FEBS Journal.2020; 287(15): 3141.     CrossRef
    • Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases
      Lucia Recinella, Giustino Orlando, Claudio Ferrante, Annalisa Chiavaroli, Luigi Brunetti, Sheila Leone
      Frontiers in Physiology.2020;[Epub]     CrossRef
    • Correlation of CCL18 with Levels of Adi-pokines in the Sera of Patients with Myocardial Infarction in a 6-Month Period: Case Series
      Atefeh GamarTalepoor, Ehsan Dowlatshahi, Mehrnoush Doroudchi
      Iranian South Medical Journal.2020; 23(3): 222.     CrossRef
    • The Mesentery, Systemic Inflammation, and Crohn’s Disease
      Edgardo D Rivera, John Calvin Coffey, Dara Walsh, Eli D Ehrenpreis
      Inflammatory Bowel Diseases.2019; 25(2): 226.     CrossRef
    • Resistin and adenylyl cyclase-associated protein 1 (CAP1) regulate the expression of genes related to insulin resistance in BNL CL.2 mouse liver cells
      Dimiter Avtanski, Karin Chen, Leonid Poretsky
      Data in Brief.2019; 25: 104112.     CrossRef
    • Proteomic profile of patients with atrial fibrillation undergoing cardiac surgery†
      Ilias P Doulamis, George Samanidis, Aspasia Tzani, Asier Antoranz, Anastasios Gkogkos, Panagiotis Konstantopoulos, Vaia Pliaka, Angeliki Minia, Leonidas G Alexopoulos, Despina N Perrea, Konstantinos Perreas
      Interactive CardioVascular and Thoracic Surgery.2019; 28(1): 94.     CrossRef
    • Angiotensin-(1-7), Adipokines and Inflammation
      Deborah de Farias Lelis, Daniela Fernanda de Freitas, Amanda Souto Machado, Thaísa Soares Crespo, Sérgio Henrique Sousa Santos
      Metabolism.2019; 95: 36.     CrossRef
    • New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
      Marta Olivera-Santa Catalina, Pedro C. Redondo, Maria P. Granados, Carlos Cantonero, Jose Sanchez-Collado, Letizia Albarran, Jose J. Lopez
      Current Medicinal Chemistry.2019; 26(22): 4119.     CrossRef
    • Myokine–adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome
      Adrian M. Gonzalez-Gil, Mariana Peschard-Franco, Elena C. Castillo, Gustavo Gutierrez-DelBosque, Victor Treviño, Christian Silva-Platas, Luisa Perez-Villarreal, Gerardo Garcia-Rivas, Leticia Elizondo-Montemayor
      Diabetology & Metabolic Syndrome.2019;[Epub]     CrossRef
    • Early Life Exposures to Perfluoroalkyl Substances in Relation to Adipokine Hormone Levels at Birth and During Childhood
      Colleen Shelly, Philippe Grandjean, Youssef Oulhote, Peter Plomgaard, Ruth Frikke-Schmidt, Flemming Nielsen, Denis Zmirou-Navier, Pal Weihe, Damaskini Valvi
      The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5338.     CrossRef
    • Overweight and obesity in childhood: Dietary, biochemical, inflammatory and lifestyle risk factors
      Samah R. Albataineh, Eman F. Badran, Reema F. Tayyem
      Obesity Medicine.2019; 15: 100112.     CrossRef
    • Effects of major adipokines and the −420 C > G resistin gene polymorphism on the long-term outcome of patients with acute ischemic stroke
      Stella Bouziana, Konstantinos Tziomalos, Antonis Goulas, Timoleon-Achilleas Vyzantiadis, Maria Papadopoulou, Athanasia Panderi, Apostolos Ι. Ηatzitolios
      International Journal of Neuroscience.2019; 129(10): 978.     CrossRef
    • The Complex Interactions Between Obesity, Metabolism and the Brain
      Romina María Uranga, Jeffrey Neil Keller
      Frontiers in Neuroscience.2019;[Epub]     CrossRef
    • Resistin: A reappraisal
      E. Acquarone, F. Monacelli, R. Borghi, A. Nencioni, P. Odetti
      Mechanisms of Ageing and Development.2019; 178: 46.     CrossRef
    • Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro‐inflammatory cytokines
      Melissa Emamalipour, Khaled Seidi, Ali Jahanban‐Esfahlan, Rana Jahanban‐Esfahlan
      Journal of Cellular Physiology.2019; 234(12): 21758.     CrossRef
    • Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis
      Vinod Chandran, Fatima Abji, Anthony V Perruccio, Rajiv Gandhi, Suzanne Li, Richard J Cook, Dafna D Gladman
      Annals of the Rheumatic Diseases.2019; 78(6): 796.     CrossRef
    • Telmisartan prevents diet-induced obesity and preserves leptin transport across the blood-brain barrier in high-fat diet-fed mice
      Franziska Schuster, Gianna Huber, Ines Stölting, Emily E. Wing, Kathrin Saar, Norbert Hübner, William A. Banks, Walter Raasch
      Pflügers Archiv - European Journal of Physiology.2018; 470(11): 1673.     CrossRef
    • Adipokines in human breast milk
      Juergen Kratzsch, Yoon Ju Bae, Wieland Kiess
      Best Practice & Research Clinical Endocrinology & Metabolism.2018; 32(1): 27.     CrossRef
    • Addressing the Perfect Storm: Biomarkers in Obesity and Pathophysiology of Cardiometabolic Risk
      Krasimira Aleksandrova, Dariush Mozaffarian, Tobias Pischon
      Clinical Chemistry.2018; 64(1): 142.     CrossRef
    • Adipocytokine Involvement in Innate Immune Mechanisms
      Paulina Żelechowska, Elżbieta Kozłowska, Joanna Pastwińska, Justyna Agier, Ewa Brzezińska-Błaszczyk
      Journal of Interferon & Cytokine Research.2018; 38(12): 527.     CrossRef
    • The effect of a garlic supplement on the pro-inflammatory adipocytokines, resistin and tumor necrosis factor-alpha, and on pain severity, in overweight or obese women with knee osteoarthritis
      Sahar Dehghani, Elham Alipoor, Ahmad Salimzadeh, Mehdi Yaseri, Mostafa Hosseini, Christine Feinle-Bisset, Mohammad Javad Hosseinzadeh-Attar
      Phytomedicine.2018; 48: 70.     CrossRef
    • Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword
      Xiao-Yan Qi, Shun-Lin Qu, Wen-Hao Xiong, Oren Rom, Lin Chang, Zhi-Sheng Jiang
      Cardiovascular Diabetology.2018;[Epub]     CrossRef
    • Usefulness of the Adipokines as Biomarkers of Ischemic Cardiac Dysfunction
      Larisa-Diana Mocan Hognogi, Cerasela-Mihaela Goidescu, Anca-Daniela Farcaş
      Disease Markers.2018; 2018: 1.     CrossRef
    • Circulating fibroblast growth factor 21 in patients with liver cirrhosis
      Sabrina Krautbauer, Lisa Rein-Fischboeck, Elisabeth M Haberl, Rebekka Pohl, Reiner Wiest, Christa Buechler
      Clinical and Experimental Medicine.2018; 18(1): 63.     CrossRef
    • Association of Cord Blood Resistin with Neonatal Birth Weight and Gestational Age
      Shahnaz Pourarian, Saeed Fotouhikia, Forough Saki
      Journal of Comprehensive Pediatrics.2018;[Epub]     CrossRef
    • Major Adipokines and the −420C>G Resistin Gene Polymorphism as Predictors of Acute Ischemic Stroke Severity and In-Hospital Outcome
      Styliani D. Bouziana, Konstantinos Tziomalos, Antonios Goulas, Timoleon-Achilleas Vyzantiadis, Athanasia Panderi, Apostolos Ι. Ηatzitolios
      Journal of Stroke and Cerebrovascular Diseases.2018; 27(4): 963.     CrossRef
    • Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis
      Stephen P. J. Macdonald, Erika Bosio, Claire Neil, Glenn Arendts, Sally Burrows, Lisa Smart, Simon G. A. Brown, Daniel M. Fatovich
      Inflammation Research.2017; 66(7): 611.     CrossRef
    • Reference values for fasting serum resistin in healthy children and adolescents
      Ulrik Lausten-Thomsen, Michael Christiansen, Paula Louise Hedley, Tenna Ruest Haarmark Nielsen, Cilius Esmann Fonvig, Oluf Pedersen, Torben Hansen, Jens-Christian Holm
      Clinica Chimica Acta.2017; 469: 161.     CrossRef
    • Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis
      Alexander Kalinkovich, Gregory Livshits
      Ageing Research Reviews.2017; 35: 200.     CrossRef
    • Is There Any Relationship between Plasma 25-Hydroxyvitamin D3, Adipokine Profiles and Excessive Body Weight in Type 2 Diabetic Patients?
      Joanna Kocot, Piotr Dziemidok, Małgorzata Kiełczykowska, Jacek Kurzepa, Grzegorz Szcześniak, Irena Musik
      International Journal of Environmental Research and Public Health.2017; 15(1): 19.     CrossRef
    • Exogenous Adipokine Peptide Resistin Protects Against Focal Cerebral Ischemia/Reperfusion Injury in Mice
      Jiangtao Zhu, Di Wu, Chenyu Zhao, Man Luo, Ronald C. Hamdy, Balvin H. L. Chua, Xingshun Xu, Zhigang Miao
      Neurochemical Research.2017; 42(10): 2949.     CrossRef
    • Adipokines in Liver Cirrhosis
      Christa Buechler, Elisabeth Haberl, Lisa Rein-Fischboeck, Charalampos Aslanidis
      International Journal of Molecular Sciences.2017; 18(7): 1392.     CrossRef
    • The role of sex steroids in white adipose tissue adipocyte function
      A E Newell-Fugate
      Reproduction.2017; 153(4): R133.     CrossRef
    • Odanacatib Inhibits Resistin-induced Cardiomyocyte Hypertrophy Through the Inactivation of ERK Signaling Pathway
      Xian Zheng, Guanchang Cheng, Jianwei Luo, Qunhui Ye, Yongzhi Deng, Lin Wu
      International Journal of Pharmacology.2017; 13(2): 212.     CrossRef
    • Linking resistin, inflammation, and cardiometabolic diseases
      Hyeong Kyu Park, Mi Kyung Kwak, Hye Jeong Kim, Rexford S. Ahima
      The Korean Journal of Internal Medicine.2017; 32(2): 239.     CrossRef
    • Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
      M. Ruscica, A. Baragetti, A.L. Catapano, G.D. Norata
      Nutrition, Metabolism and Cardiovascular Diseases.2017; 27(5): 379.     CrossRef
    • Differences in Mean Levels of Maternal Resistin Serum between Early Onset Preeclampsia (EOPE) and Late Onset Preeclampsia (LOPE)
      Yusrawati ., P. Alfajra, R. Machmud
      Research Journal of Obstetrics and Gynecology.2016; 10(1): 1.     CrossRef
    • Secret talk between adipose tissue and central nervous system via secreted factors—an emerging frontier in the neurodegenerative research
      Avinash Parimisetty, Anne-Claire Dorsemans, Rana Awada, Palaniyandi Ravanan, Nicolas Diotel, Christian Lefebvre d’Hellencourt
      Journal of Neuroinflammation.2016;[Epub]     CrossRef
    • The role of adipokines in ischemic stroke risk stratification
      Styliani Bouziana, Konstantinos Tziomalos, Antonios Goulas, Apostolos Ι Ηatzitolios
      International Journal of Stroke.2016; 11(4): 389.     CrossRef
    • The endocrine function of human placenta: an overview
      Mariana A. Costa
      Reproductive BioMedicine Online.2016; 32(1): 14.     CrossRef
    • Ursolic acid plays a protective role in obesity-induced cardiovascular diseases
      Yu-Ting Lin, Ya-Mei Yu, Weng-Cheng Chang, Su-Yin Chiang, Hsu-Chin Chan, Ming-Fen Lee
      Canadian Journal of Physiology and Pharmacology.2016; 94(6): 627.     CrossRef
    • Determinants of body weight regulation in humans
      Milene Moehlecke, Luis Henrique Canani, Lucas Oliveira Junqueira e Silva, Manoel Roberto Maciel Trindade, Rogerio Friedman, Cristiane Bauermann Leitão
      Archives of Endocrinology and Metabolism.2016; 60(2): 152.     CrossRef
    • Sitagliptin decreases ventricular arrhythmias by attenuated glucose-dependent insulinotropic polypeptide (GIP)-dependent resistin signalling in infarcted rats
      Tsung-Ming Lee, Wei-Ting Chen, Nen-Chung Chang
      Bioscience Reports.2016;[Epub]     CrossRef
    • Les adipokines : état des lieux et nouveautés
      J.-P. Bastard, C. Bastard, S. Fellahi, C. Vatier, J. Capeau, B. Fève
      Obésité.2016; 11(3): 181.     CrossRef
    • Factors that promote macrophage homing to adipose tissue in metabolic syndrome
      Ishwarlal Jialal, Beverley Adams-Huet, Sridevi Devaraj
      Journal of Diabetes and its Complications.2016; 30(8): 1434.     CrossRef
    • Uncovering Factors Related to Pancreatic Beta-Cell Function
      Aoife M. Curran, Miriam F. Ryan, Elaine Drummond, Eileen R. Gibney, Michael J. Gibney, Helen M. Roche, Lorraine Brennan, Nigel Irwin
      PLOS ONE.2016; 11(8): e0161350.     CrossRef
    • Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans
      X. Huang, Z. Yang
      Journal of Endocrinological Investigation.2016; 39(6): 607.     CrossRef
    • Adipocytokines in renal transplant recipients
      Kristof Nagy, Shankar Prasad Nagaraju, Connie M. Rhee, Zoltan Mathe, Miklos Z. Molnar
      Clinical Kidney Journal.2016; 9(3): 359.     CrossRef
    • Endocrine alterations from concentric vs. eccentric muscle actions: A brief review
      Robert R. Kraemer, V. Daniel Castracane
      Metabolism.2015; 64(2): 190.     CrossRef
    • Non-traditional cytokines: How catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system
      Mark A. Barnes, Monica J. Carson, Meera G. Nair
      Cytokine.2015; 72(2): 210.     CrossRef
    • Local and serum levels of adipokines in patients with obesity after periodontal therapy: one‐year follow‐up
      Tiago Eduardo Dias Gonçalves, Glaucia Santos Zimmermann, Luciene Cristina Figueiredo, Monique de Carvalho Souza, Daniele Ferreira da Cruz, Marta Ferreira Bastos, Hélio Doyle Pereira da Silva, Poliana Mendes Duarte
      Journal of Clinical Periodontology.2015; 42(5): 431.     CrossRef
    • Newborn Adipokines and Birth Outcomes
      Edwina H. Yeung, Alexander C. McLain, Nancy Anderson, David Lawrence, Nansi S. Boghossian, Charlotte Druschel, Erin Bell
      Paediatric and Perinatal Epidemiology.2015; 29(4): 317.     CrossRef
    • The effect of a preparation of minerals, vitamins and trace elements on the cardiac gene expression pattern in male diabetic rats
      Márta Sárközy, Gergő Szűcs, Márton Pipicz, Ágnes Zvara, Katalin Éder, Veronika Fekete, Csilla Szűcs, Judit Bárkányi, Csaba Csonka, László G. Puskás, Csaba Kónya, Péter Ferdinandy, Tamás Csont
      Cardiovascular Diabetology.2015;[Epub]     CrossRef
    • Diet-induced variability of the resistin gene (Retn) transcript level and methylation profile in rats
      Joanna Nowacka-Woszuk, Ewa Pruszynska-Oszmalek, Maciej Szydlowski, Slawomir Sadkowski, Izabela Szczerbal
      BMC Genetics.2015;[Epub]     CrossRef
      A. T. Teplyakov, Sh. D. Akhmedov, T. Ye. Suslova, А. V. Andriyanova, A. V. Kuznetsova, N. V. Protopopova, V. V. Kalyuzhin, O. N. Nasanova
      Bulletin of Siberian Medicine.2015; 14(5): 73.     CrossRef
    • The Effects of a Single Developmentally Entrained Pulse of Testosterone in Female Neonatal Mice on Reproductive and Metabolic Functions in Adult Life
      Hyeran Jang, Shalender Bhasin, Tyler Guarneri, Carlo Serra, Mary Schneider, Mi-Jeong Lee, Wen Guo, Susan K. Fried, Karol Pencina, Ravi Jasuja
      Endocrinology.2015; 156(10): 3737.     CrossRef
    • The Resin fromProtium heptaphyllumPrevents High-Fat Diet-Induced Obesity in Mice: Scientific Evidence and Potential Mechanisms
      Karine Maria Martins Bezerra Carvalho, José Delano Barreto Marinho Filho, Tiago Sousa de Melo, Ana Jérsia Araújo, Josiane da Silva Quetz, Maria do Perpétuo Socorro Saldanha da Cunha, Karina Moura de Melo, Armenio Andre de Carvalho Almeida da Silva, Adrian
      Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1.     CrossRef
    • Evolution of the Vertebrate Resistin Gene Family
      Qingda Hu, Huanran Tan, David M. Irwin, Marc Robinson-Rechavi
      PLOS ONE.2015; 10(6): e0130188.     CrossRef
    • Obesity, adipokines and neuroinflammation
      Argel Aguilar-Valles, Wataru Inoue, Christoph Rummel, Giamal N. Luheshi
      Neuropharmacology.2015; 96: 124.     CrossRef
    • Adipokines at the crossroad between obesity and cardiovascular disease
      Filippo Molica, Sandrine Morel, Brenda Kwak, Françoise Rohner-Jeanrenaud, Sabine Steffens
      Thrombosis and Haemostasis.2015; 113(03): 553.     CrossRef
    • Resistin – 420 C/G polymorphism and serum resistin level in Iranian patients with gestational diabetes mellitus
      Mohammad Ali Takhshid, Zinab Zare
      Journal of Diabetes & Metabolic Disorders.2015;[Epub]     CrossRef
    • Ictal adipokines are associated with pain severity and treatment response in episodic migraine
      Nu Cindy Chai, Bizu Gelaye, Gretchen E. Tietjen, Paul D. Dash, Barbara A. Gower, Linda W. White, Thomas N. Ward, Ann I. Scher, B. Lee Peterlin
      Neurology.2015; 84(14): 1409.     CrossRef
    • Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration
      Lindsay J. Spielman, Jonathan P. Little, Andis Klegeris
      Journal of Neuroimmunology.2014; 273(1-2): 8.     CrossRef
    • Wild Blueberries (Vaccinium myrtillus) Alleviate Inflammation and Hypertension Associated with Developing Obesity in Mice Fed with a High-Fat Diet
      Otto T. Mykkänen, Anne Huotari, Karl-Heinz Herzig, Thomas W. Dunlop, Hannu Mykkänen, Pirkka V. Kirjavainen, Michael Müller
      PLoS ONE.2014; 9(12): e114790.     CrossRef
    • Role of fat and adipokines in intestinal inflammation
      LeaI Kredel, Arvind Batra, Britta Siegmund
      Current Opinion in Gastroenterology.2014; 30(6): 559.     CrossRef
    • 13C metabolic flux analysis shows that resistin impairs the metabolic response to insulin in L6E9 myotubes
      Shirley Guzmán, Silvia Marin, Anibal Miranda, Vitaly A Selivanov, Josep J Centelles, Romain Harmancey, Fatima Smih, Annie Turkieh, Yves Durocher, Antonio Zorzano, Philippe Rouet, Marta Cascante
      BMC Systems Biology.2014;[Epub]     CrossRef
    • Bee Pollen Improves Muscle Protein and Energy Metabolism in Malnourished Old Rats through Interfering with the Mtor Signaling Pathway and Mitochondrial Activity
      Jérôme Salles, Nicolas Cardinault, Véronique Patrac, Alexandre Berry, Christophe Giraudet, Marie-Laure Collin, Audrey Chanet, Camille Tagliaferri, Philippe Denis, Corinne Pouyet, Yves Boirie, Stéphane Walrand
      Nutrients.2014; 6(12): 5500.     CrossRef

    • PubReader PubReader
    • Cite this Article
      Cite this Article
      export Copy Download
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      • Citation for the content below
      Resistin in Rodents and Humans
      Diabetes Metab J. 2013;37(6):404-414.   Published online December 12, 2013
    • XML DownloadXML Download
    Park HK, Ahima RS. Resistin in Rodents and Humans. Diabetes Metab J. 2013;37(6):404-414.

    Diabetes Metab J : Diabetes & Metabolism Journal
    Close layer